Tanezumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | NGF |
| Clinical data | |
| Other names | RN624 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6464H9942N1706O2026S46 |
| Molar mass | 145.4 kg/mol g·mol−1 |
  (what is this?) (verify) | |
Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor. It was developed by Pfizer as a treatment for pain.[1]
In 2009 there was a Phase III trial for knee pain due to osteoarthritis (OA).[2] Another phase III trial for hip pain in OA [3] was halted in June 2010 when some patients needed hip replacement.[4]
Tanezumab is undergoing Phase II clinical trials for the treatment of various pain entities, including chronic low back pain, bone cancer pain, and interstitial cystitis.[5]
In march of 2012 the Anti-NGF Testing - FDA Committee voted in favor of a continuation of the development of nerve-blocking medications, as long as certain safety precautions were observed.
A phase III trial published in 2013 found tanezumab was superior to placebo for painful hip osteoarthritis.[6]
References
- ^ N05, American Medical Association.
- ^ "Tanezumab in Osteoarthritis of the Knee". 2009
- ^ "Tanezumab in Osteoarthritis Of The Hip".
- ^ http://www.genengnews.com/gen-news-highlights/trials-halted-as-pfizer-s-tanezumab-shown-to-worsen-osteoarthritis/81243572/
- ^ "Phase II trials involving Tanezumab".
- ^ "Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial". Arthritis Rheum. 65: 1795–803. Jul 2013. doi:10.1002/art.37950. PMID 23553790.
External links
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This analgesic-related article is a stub. You can help Wikipedia by expanding it. |